Peer Exchange

In this OncLive Peer Exchange series, a panel of experts discusses the latest advancements in the management of gynecological cancers, highlighting updates from ESMO 2024, including treatment paradigms for advanced ovarian, cervical, and endometrial cancers, biomarker testing strategies, and emerging therapies such as antibody-drug conjugates.

Panelists discuss how recent clinical trials and innovative therapies are reshaping the treatment landscape for small cell lung cancer, emphasizing the importance of personalized approaches and multidisciplinary strategies to improve patient outcomes.

Elias Jabbour, MD; Evandro D. Bezerra, MD; Lori Muffly, MD; Jae H. Park, MD, and Gregory W. Roloff, MD,review the role of CAR T-cell therapy\ for relapsed/refractory acute lymphoblastic leukemia, address adverse event management and supportive care, and highlight significant updates presented at the American Society of Clinical Oncology and European Hematology Association 2024 conferences.

Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.

Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL.

John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.

Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.

Kelly McCann, MD, PhD, drives a discussion surrounding key topics and highlights in HR+ breast cancer treatment as presented at ASCO 2024.

A panel of experts on HER2+ breast cancer has a comprehensive discussion on recent data updates and how they might impact clinical practice.

Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), discussing current treatments and ongoing clinical trials in this field.

A panel of experts on colorectal cancer provides comprehensive insights on MRD testing within the disease space, highlight the general landscape, recent data, ongoing trials, and future directions.

A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.

Following ASCO GU 2024, a panel of GU medical oncologists discuss recent updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape.

Aparna Parikh, MD, leads a panel discussion surrounding updates and advancements in the metastatic colorectal cancer treatment landscape.

A panel of medical oncologists specializing in the treatment of renal cell carcinoma have a comprehensive discussion on updates in the treatment of advanced RCC following ASCO GU 2024.